Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
QuantumLeap Healthcare Collaborative
Eli Lilly and Company
Revolution Medicines, Inc.
Hoffmann-La Roche
AbbVie
Astellas Pharma Inc
Amgen
Norwegian University of Science and Technology
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
Università Vita-Salute San Raffaele
University of Kentucky
Tesaro, Inc.
AbbVie
Weill Medical College of Cornell University
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Tesaro, Inc.
AbbVie
Sanofi
National Institutes of Health Clinical Center (CC)
DEKA Biosciences
Mario Negri Institute for Pharmacological Research
Shandong Cancer Hospital and Institute
Northwell Health
Spanish Lung Cancer Group
Ohio State University Comprehensive Cancer Center
Blueprint Medicines Corporation
GlaxoSmithKline
Eli Lilly and Company
Actuate Therapeutics Inc.
Aetion, Inc.
iTeos Therapeutics
Aetion, Inc.
Cantargia AB
University of California, San Diego
MedImmune LLC
The First Affiliated Hospital of Guangzhou Medical University
Kyowa Kirin Co., Ltd.
Zhongnan Hospital
Nanfang Hospital, Southern Medical University
Loyola University
Blueprint Medicines Corporation
Centus Biotherapeutics Limited
Roswell Park Cancer Institute
Noxopharm Limited
AbbVie